Pharmacological targeting of the pseudokinase Her3

Ting Xie, Sang M in Lim, Kenneth D. Westover, Michael E. Dodge, Dalia Ercan, Scott B. Ficarro, Durga Udayakumar, Deepak Gurbani, Hyun S eop Tae, Steven M. Riddle, Taebo Sim, Jarrod A. Marto, Pasi A. Jänne, Craig M. Crews, Nathanael S. Gray

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and ∼60 other pseudokinases found in human cells.

Original languageEnglish
Pages (from-to)1006-1012
Number of pages7
JournalNature Chemical Biology
Volume10
Issue number12
DOIs
Publication statusPublished - 2014 Dec 1
Externally publishedYes

Fingerprint

Adenosine Triphosphate
Adamantane
Pharmacology
Ligands
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplasms
Phosphotransferases
Binding Sites
Cell Line
N-(2-(4-(3-(3-acrylamido-4-phenoxyphenyl)-4-amino-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)ethyl)-4-(1-adamantanyl)-2-methylbutanamide
TX1-85-1

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Xie, T., Lim, S. M. I., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., ... Gray, N. S. (2014). Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology, 10(12), 1006-1012. https://doi.org/10.1038/nchembio.1658

Pharmacological targeting of the pseudokinase Her3. / Xie, Ting; Lim, Sang M in; Westover, Kenneth D.; Dodge, Michael E.; Ercan, Dalia; Ficarro, Scott B.; Udayakumar, Durga; Gurbani, Deepak; Tae, Hyun S eop; Riddle, Steven M.; Sim, Taebo; Marto, Jarrod A.; Jänne, Pasi A.; Crews, Craig M.; Gray, Nathanael S.

In: Nature Chemical Biology, Vol. 10, No. 12, 01.12.2014, p. 1006-1012.

Research output: Contribution to journalArticle

Xie, T, Lim, SMI, Westover, KD, Dodge, ME, Ercan, D, Ficarro, SB, Udayakumar, D, Gurbani, D, Tae, HSE, Riddle, SM, Sim, T, Marto, JA, Jänne, PA, Crews, CM & Gray, NS 2014, 'Pharmacological targeting of the pseudokinase Her3', Nature Chemical Biology, vol. 10, no. 12, pp. 1006-1012. https://doi.org/10.1038/nchembio.1658
Xie T, Lim SMI, Westover KD, Dodge ME, Ercan D, Ficarro SB et al. Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology. 2014 Dec 1;10(12):1006-1012. https://doi.org/10.1038/nchembio.1658
Xie, Ting ; Lim, Sang M in ; Westover, Kenneth D. ; Dodge, Michael E. ; Ercan, Dalia ; Ficarro, Scott B. ; Udayakumar, Durga ; Gurbani, Deepak ; Tae, Hyun S eop ; Riddle, Steven M. ; Sim, Taebo ; Marto, Jarrod A. ; Jänne, Pasi A. ; Crews, Craig M. ; Gray, Nathanael S. / Pharmacological targeting of the pseudokinase Her3. In: Nature Chemical Biology. 2014 ; Vol. 10, No. 12. pp. 1006-1012.
@article{aea8685e476042f0983898ef02a90cfc,
title = "Pharmacological targeting of the pseudokinase Her3",
abstract = "Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and ∼60 other pseudokinases found in human cells.",
author = "Ting Xie and Lim, {Sang M in} and Westover, {Kenneth D.} and Dodge, {Michael E.} and Dalia Ercan and Ficarro, {Scott B.} and Durga Udayakumar and Deepak Gurbani and Tae, {Hyun S eop} and Riddle, {Steven M.} and Taebo Sim and Marto, {Jarrod A.} and J{\"a}nne, {Pasi A.} and Crews, {Craig M.} and Gray, {Nathanael S.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1038/nchembio.1658",
language = "English",
volume = "10",
pages = "1006--1012",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Pharmacological targeting of the pseudokinase Her3

AU - Xie, Ting

AU - Lim, Sang M in

AU - Westover, Kenneth D.

AU - Dodge, Michael E.

AU - Ercan, Dalia

AU - Ficarro, Scott B.

AU - Udayakumar, Durga

AU - Gurbani, Deepak

AU - Tae, Hyun S eop

AU - Riddle, Steven M.

AU - Sim, Taebo

AU - Marto, Jarrod A.

AU - Jänne, Pasi A.

AU - Crews, Craig M.

AU - Gray, Nathanael S.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and ∼60 other pseudokinases found in human cells.

AB - Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and ∼60 other pseudokinases found in human cells.

UR - http://www.scopus.com/inward/record.url?scp=84920590896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920590896&partnerID=8YFLogxK

U2 - 10.1038/nchembio.1658

DO - 10.1038/nchembio.1658

M3 - Article

VL - 10

SP - 1006

EP - 1012

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 12

ER -